加载中
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
收盘时
US$6.49
−US$0.15 · -2.26%
盘后
US$6.28
−US$0.21 · -3.24%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
日内区间
当前US$6.49
52周区间
当前US$6.49
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
45
合理估值
情绪
45
多空交织
风险
75
高风险
动量
20
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
日内区间
当前US$6.49
52周区间
当前US$6.49
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 218.5万 USD | — | — | — | — |
| 毛利 | −218.5万 USD | — | — | — | — |
| 研究与开发 | 4492.3万 USD | 4148.8万 USD | 4793.1万 USD | 5419.9万 USD | 5019.2万 USD |
| 销售、一般及管理费用 | 1269.3万 USD | 1571.8万 USD | 1970.6万 USD | 2171万 USD | 2057.3万 USD |
| 营业费用 | 5543.1万 USD | 5974.8万 USD | 6763.7万 USD | 7590.9万 USD | 7076.5万 USD |
| 利息收入 | — | — | — | 116.7万 USD | 1319 USD |
| 利息支出 | — | — | — | — | 7.7万 USD |
| 折旧和摊销 | 218.5万 USD | 286.5万 USD | 368.4万 USD | 412.4万 USD | 417.7万 USD |
| 营业利润 | −5761.6万 USD | −5974.8万 USD | −6763.7万 USD | −7590.9万 USD | −7076.5万 USD |
| 净利润 | −5584.4万 USD | −5565.4万 USD | −6272.3万 USD | −7473.3万 USD | −6938.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.00
上涨空间 208.17%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年7月14日 | 1:12 | — | — |
已生效 2025年7月14日
1:12
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI78.77万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF21.45万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Micro-Cap ETFIWC7.53万0.01%13.17亿 USD0.60%US$179.6-1.13%
U.S. Micro Cap Portfolio ETFDFMC1.8万0.00%75.44亿 USD0.43%US$57.78+0.14%
Dimensional - US Core Equity 2 ETFDFAC391.760.00%885.59亿 USD0.21%US$45.35+0.09%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
